| 3.91 0.04 (1.03%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.86 | 1-year : | 6.82 |
| Resists | First : | 5.02 | Second : | 5.84 |
| Pivot price | 4.48  |
|||
| Supports | First : | 3.7 | Second : | 3.07 |
| MAs | MA(5) : | 4.15 |
MA(20) : | 4.54 |
| MA(100) : | 4.32  |
MA(250) : | 3.5 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 10.5 |
D(3) : | 12 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 7.22 | Low : | 2.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RLMD ] has closed above bottom band by 3.6%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.1 - 4.13 | 4.13 - 4.15 |
| Low: | 3.76 - 3.79 | 3.79 - 3.82 |
| Close: | 3.87 - 3.91 | 3.91 - 3.95 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Tue, 23 Apr 2024
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 3.3% - MarketBeat
Mon, 22 Apr 2024
Is the Options Market Predicting a Spike in Relmada (RLMD) Stock? - Yahoo Movies Canada
Sat, 20 Apr 2024
Bullish Relmada Therapeutics Insiders Loaded Up On US$695.2k Of Stock - Simply Wall St
Thu, 21 Mar 2024
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop (NASDAQ:RLMD) - Seeking Alpha
Wed, 20 Mar 2024
Relmada Therapeutics trims losses, slashes research costs - Green Market Report
Tue, 19 Mar 2024
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 46.3 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,750 (K) |
| EPS | -3.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.83 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.8 % |
| Return on Equity (ttm) | -87.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.2 |
| PEG Ratio | 0 |
| Price to Book value | 1.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|